Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
מצבים רפואיים
Multiple Myeloma, Newly Diagnosed · Multiple Myeloma (MM)
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
University of Alabama at Birmingham, Birmingham, Alabama, United States
Contact: Principal Investigator (Gayathri Ravi, MD)Colorado Blood Cancer Institute, Denver, Colorado, United States
Contact: Principal Investigator (Henning Schade, MD)University of Iowa, Iowa City, Iowa, United States
Contact: Principal Investigator (Christopher Strouse, MD)University of North Carolina, Chapel Hill, North Carolina, United States
Contact: Principal Investigator (Samuel Rubinstein, MD)Oncology Hematology Care, Cincinnati, Ohio, United States
The Ohio State University- The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
Contact: Principal Investigator (Naresh Bumma, MD)SCRI Oncology Partners, Nashville, Tennessee, United States
Contact: Principal Investigator (Hans Lee, MD)University of Texas Southwestern, Dallas, Texas, United States
Contact: Principal Investigator (Aimaz Afrough, MD)Virginia Oncology Associates, Norfolk, Virginia, United States
Contact: Principal Investigator (Scott Cross, MD)University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States
Contact: Principal Investigator (Timothy Schmidt, MD)Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Contact: Principal Investigator (Ravi Narra, MD)
מובילי המחקר
Henning Schade, MD
Study Chair
Colorado Blood Cancer Institute